Introduction/Background*Epithelial ovarian cancer (EOC) is the fifth most lethal cancer in women in Portugal. Despite advances in surgical and anti-cancer systemic treatment (SACT), EOC overall prognosis remains poor. The objective of this study is to describe SACT outcomes patterns, including target therapies (bevacizumab and PARPi) using real-world data from a comprehensive cancer center, which serves Northern Portugal population.

Methodology Retrospective observational cohort study. We reviewed medical records of diagnosed EOC patients (pts) who were eligible for SACT, between 2012 and 2018. Primary endpoint was overall survival (OS). Secondary endpoints were description of platinum sensibility patterns and lines of treatment (LOT). Descriptive analysis of main demographic, clinical and treatment variables were performed. Kaplan-Meier method was used for OS. Uni and multivariable analysis were done using Cox proportional hazard analysis

Result(s)*We identified 268 EOC pts with median age of 66 (24-94). Debulking surgery was performed in 119 pts (44.4%). Most were stage III-IV FIGO (200, 74.6%) and had high-grade serous morphology (103, 38.6%). BRCA mutations (germline and/or somatic) were detected in 7.6% of 131 tested pts. A third of pts never relapsed (86, 32.1%). Platinum-based CT was the 1^st LOT in 173 pts (64,6%). After relapse or progression, primary platinum resistance (PPR) was present in 34 (19.7%), partial platinum sensibility in 29 (16.8%) and full platinum sensibility in 24 (13.9%). Of the 180 pts who progressed, 41 (22.8%) were submitted to 2^nd SACT and 20 (11.1%) to 3^rd SACT. Median number of LOT were 2 (1-8). Bevacizumab concomitant with CT was used in 45 pts (16.8%) at some point. PARPi was used in 23 (8.6%) pts as maintenance treatment after ≥2 platinum-based CT complete or partial response. Median OS was 25.5 months [IC95% 19.55-35.42], which was significantly worse for more advanced disease [HR 8.46 IC95% 4.13-17.31] and PPR [HR 2.72 IC95% 1.63-4.54].

Conclusion*Our results confirm that EOC outcomes are modest and in line with other published cohorts. Multicentric real-world studies are needed to evaluate how innovative targeted therapies, recently introduced in the daily clinical practice, will change the course of this disease.